Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes
Michael J. Haller(University of Florida), Desmond Schatz(University of Florida), Jonathan J. Shuster(Health Outcomes Solutions (United States)), Todd M. Brusko(University of Florida), Mark A. Atkinson(University of Florida), Baiming Zou, Stephen M. Rosenthal(University of California, San Francisco), Clayton E. Mathews(University of Florida), Peter A. Gottlieb(University of Colorado Health), Clive Wasserfall(University of Florida), Maigan A. Hulme(University of Florida), Stephen E. Gitelman(University of California, San Francisco), Aaron W. Michels(University of Colorado Anschutz Medical Campus)
Cited by 164
Related Papers
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
Type 1 diabetes
|The Lancet|2013|2.7k
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
|The Lancet|2001|1.5k
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
|Diabetes Care|2015|1.2k
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
|New England Journal of Medicine|1994|1.1k